Quadruple Versus Sequential Therapy for Helicobacter Pylori Eradication
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
Helicobacter pylori (HP), a bacterium present in many people's stomachs, is one of the major
causes of ulcers and cancers. Up to 20% of patients infected with H. pylori may develop
peptic ulcers. However, failure rate is rising due to multiple resistant H. pylori infection.
The eradication rate of first line clarithromycin based therapy has fallen to below 80%. Both
quadruple and sequential treatment regime has been proposed as the first-line empirical
regime. Nevertheless, comparison in terms of efficacy and side effects between the two regime
remained unknown. The aim of this clinical trial is to compare the efficacy and tolerability
of H. pylori eradication with a 10-day quadruple therapy versus sequential therapy as
empirical first and second line treatment.